Qiang Zhao
Director/Board Member at Shanghai Haihe Biopharma Co., Ltd.
Qiang Zhao active positions
| Companies | Position | Start | End |
|---|---|---|---|
Shanghai Haihe Biopharma Co., Ltd.
 Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Director/Board Member | 07/09/2020 | - |
| Independent Dir/Board Member | 07/09/2020 | - |
Career history of Qiang Zhao
Former positions of Qiang Zhao
| Companies | Position | Start | End |
|---|---|---|---|
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Director/Board Member | 25/05/2017 | 09/06/2023 |
| Independent Dir/Board Member | 25/05/2017 | 09/06/2023 | |
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Director/Board Member | 11/09/2014 | - |
| Independent Dir/Board Member | 11/09/2014 | - |
Statistics
International
| China | 4 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
Sectoral
| Utilities | 2 |
| Producer Manufacturing | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Utilities |
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Producer Manufacturing |
| Private companies | 1 |
|---|---|
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Commercial Services |
- Stock Market
- Insiders
- Qiang Zhao
- Experience
